Physician profile
Jon Carter Benson
NPI 1922030956
$19,100.79
in general payments reported to CMS, 2019-2025
36 companies · $4,695 in 2025
The $4,695 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,754 · 2022: $3,609 · 2023: $4,303 · 2024: $3,739 · 2025: $4,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,166 · Education: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,935.16 |
| Consulting Fee | $1,165.50 |
| Education | $636.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,941.38 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $2,216.09 | 2021-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,756.73 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $1,453.44 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,380.91 | 2021-2025 | Tremfya |
| Genzyme Corporation | $1,275.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,160.73 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,057.20 | 2021-2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $940.89 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $939.17 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $685.49 | 2021-2025 | |
| Journey Medical Corporation | $680.28 | 2021-2025 | |
| Amgen INC. | $476.64 | 2021-2024 | Otezla |
| Galderma Laboratories, L.P. | $465.78 | 2021-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $389.12 | 2021-2024 | Arazlo, Siliq, Targretin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $325.03 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.13 | 2023-2024 | Cyltezo, Spevigo |
| Biofrontera INC. | $136.54 | 2022-2025 | Ameluz, Bf-Rhodoled, Xepi |
| Pfizer INC. | $95.73 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $85.79 | 2022 | |
| Dermavant Sciences, INC. | $63.91 | 2023 | Vtama |
| Almirall LLC | $49.56 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $48.76 | 2023-2025 | |
| Boston Scientific Corporation | $40.28 | 2025 | Bodyguardian |
| Mimedx Group, INC. | $39.09 | 2024 | |
| Verrica Pharmaceuticals INC. | $39.09 | 2024 | Ycanth |
| Genentech USA, INC. | $38.54 | 2021-2024 | Erivedge |
| Sandoz INC. | $35.78 | 2023-2024 | Hyrimoz |
| Mylan Institutional INC. | $23.09 | 2023 | |
| Fresenius Kabi USA, LLC | $18.20 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.04 | 2024 | Acthar |
| Nabriva Therapeutics, Plc | $16.50 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $16.07 | 2025 | Neo-Synalar |
| Vyne Pharmaceuticals INC. | $14.49 | 2021 | |
| Dermira, INC. | $14.15 | 2021 | |
| Organon LLC | $5.20 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.